FDA Panel Votes 5-2 Against Kit Form of NTP Test.MAYWOOD, N.J. -- Nymox Pharmaceutical Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : NYMX NYMX New York Mercantile Exchange ) announced today that on Friday, July 15, an FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. advisory panel voted 5-2 against approval of the kit form of the Company's NTP (Network Time Protocol) A TCP/IP protocol used to synchronize the real time clock in computers, network devices and other electronic equipment that is time sensitive. It is also used to maintain the correct time in NTP-based wall and desk clocks. test (AlzheimAlert(TM)). AlzheimAlert(TM) remains approved for sale in the U.S. as a laboratory testing service through the Company's clinical reference laboratory in New Jersey. NASDAQ halted NYMX trading on Friday during the panel meeting in order to maintain an orderly market. "We are very pleased to have had the opportunity to present the results of the blinded 9 center trial which showed that 89.5% of clinical cases of probable AD had elevated NTP and 91% of definite non-AD had normal NTP levels," said Dr. Paul Averback, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Nymox. "The panel, however, felt that more data was required for approval, including, for example, post-mortem verification and clarification of how to use the test results. We anticipate working with FDA towards fulfilling the further data requirements that the agency may have in conjunction with the panel suggestions." Nymox Pharmaceutical Corporation is a biotechnology company engaged in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. Currently Nymox has three products on the market, and a healthy pipeline of drug and diagnostic products. The Company also has several hundred patents and patent applications. Nymox currently markets AlzheimAlert(TM) as a CLIA-certified laboratory testing service in the U.S. and as a kit in the European Union as a result of its certification with a CE Mark. The Company has successfully completed two U.S. Phase 1-2 clinical trials for NX-1207, its drug for benign prostatic hyperplasia benign prostatic hyperplasia n. Abbr. BPH A nonmalignant enlargement of the prostate gland commonly occurring in men after the age of 50, and sometimes leading to compression of the urethra and obstruction of the flow of urine. (BPH BPH abbr. benign prostatic hyperplasia BPH Benign prostatic hypertrophy, a very common noncancerous cause of prostatic enlargement in older men. ). The Company markets NicAlert(TM) and TobacAlert(TM) tests for measuring tobacco product exposure. Nymox has a number of drugs in development for Alzheimer's disease, oncology, and infectious disease. The Company will hold a teleconference call for shareholders at 4:30 p.m. today. Call 800-936-9669 after 12:00 p.m. EST for details. More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669. This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion